Patient-reported outcomes (PROs) for tivozanib (TIVO) plus nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.

被引：0
|
作者：
Beckermann, Katy
Choueiri, Toni K.
Motzer, Robert J.
Barthelemy, Philippe
Iacovelli, Roberto
Emambux, Sheik
Molina-Cerrillo, Javier
Garmezy, Benjamin
Barata, Pedro C.
Mckay, Rana R.
Chehrazi-Raffle, Alex
Hammers, Hans J.
Heng, Daniel Yick Chin
Braendle, Edgar E.
Lebedinsky, Claudia
Jin, Bo
Albiges, Laurence
Mcgregor, Bradley Alexander
机构：
[1] Vanderbilt Univ, Nashville, TN USA
[2] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[3] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, New York, NY USA
[4] Inst Cancerol Strasbourg Europe ICANS, Dept Med Oncol, Strasbourg, France
[5] Univ Cattolica Sacro Cuore, Rome, Italy
[6] Ctr Hosp Univ Poitiers, Poitiers, France
[7] Hosp Univ Ramon & Cajal, Med Oncol Dept, Madrid, Spain
[8] Sarah Cannon Res Inst, Nashville, TN USA
[9] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[10] Univ Calif San Diego, La Jolla, CA USA
[11] City Hope Comprehens Canc Ctr, Duarte, CA USA
[12] UT Southwestern, Dept Internal Med, Div Hematol & Oncol, Dallas, TX USA
[13] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[14] Aveo Oncol, Boston, MA USA
[15] Inst Gustave Roussy, Villejuif, France
[16] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.459
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 17 条
  • [1] Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3TiNivo-2 Study
    Choueiri, Toni K.
    Albiges, Laurence
    Barthelemy, Philippe
    Iacovelli, Roberto
    Emambux, Sheik
    Molina-Cerrillo, Javier
    Garmezy, Benjamin
    Barata, Pedro
    Basu, Arnab
    Bourlon, Maria
    Moon, Helen
    Ratta, Raffaele
    McKay, Rana R.
    Chehrazi-Raffle, Alexander
    Hammers, Hans
    Heng, Daniel Y. C.
    Braendle, Edgar
    Beckermann, Kathryn E.
    McGregor, Bradley A.
    Motzer, Robert J.
    LANCET, 2024, 404 (10460):
  • [2] TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor
    Choueiri, Toni K.
    Albiges, Laurence
    Mckay, Rana R.
    Pal, Sumanta K.
    Hammers, Hans J.
    Heng, Daniel Yick Chin
    Beckermann, Katy
    Kasturi, Vijay
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.
    Choueiri, Toni K.
    Albiges, Laurence
    Hammers, Hans J.
    Mckay, Rana R.
    Heng, Daniel Yick Chin
    Beckermann, Katy
    Kasturi, Vijay
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [4] Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial
    Bourlon, Maria T.
    Albiges, Laurence
    Chacon, Matias Rodrigo
    Cutuli, Hernan
    Zurawski, Bogdan
    Mota, Jose Mauricio
    Magri, Ignacio
    Burotto, Mauricio
    Luz, Murilo
    Menezes, Juliana
    Ruiz, Eduardo Patricio Yanez
    Maruzzo, Marco
    Bracarda, Sergio
    Prusty, Subhransu
    Rathod, Dhanrajsinh
    Yu, Zhuoxin
    Gurm, Balmeet
    Dixon, Matthew
    George, Saby
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
    Powles, Thomas
    Albiges, Laurence
    Jalkanen, Katriina Johanna
    De Velasco, Guillermo
    Burotto, Mauricio
    Ghatalia, Pooja
    Suarez, Cristina
    Lam, Elaine T.
    Iacovelli, Roberto
    Gumus, Mahmut
    Verzoni, Elena
    Kollmannsberger, Christian K.
    Stadler, Walter Michael
    Venugopal, Balaji
    Shinde, Reshma
    Saretsky, Todd L.
    He, Li
    Vickery, Donna
    Choueiri, Toni K.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 361 - 361
  • [6] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
    Cella, David
    Gruenwald, Viktor
    Escudier, Bernard
    Hammers, Hans J.
    George, Saby
    Nathan, Paul
    Grimm, Marc-Oliver
    Rini, Brian, I
    Doan, Justin
    Ivanescu, Cristina
    Paty, Jean
    Mekan, Sabeen
    Motzer, Robert J.
    LANCET ONCOLOGY, 2019, 20 (02): : 297 - 310
  • [7] Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
    Choueiri, Toni K.
    Albiges, Laurence
    Tomczak, Piotr
    Suarez, Cristina
    Voss, Martin H.
    de Velasco, Guillermo
    Chahoud, Jad
    Procopio, Giuseppe
    Mahammedi, Hakim
    Zengerling, Friedemann
    Kim, Chan
    Gupta, Suyasha
    Bergthold, Guillaume
    Liu, Bo
    Kalaitzidou, Melania
    Huseni, Mahrukh A.
    Scheffold, Christian
    Powles, Thomas
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA4500 - LBA4500
  • [8] Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma (RCC) patients: Results from 3-year follow-up of the phase 2 pilot study.
    Tsimafeyeu, Ilya
    Gafanov, Rustem
    Myslevtsev, Igor
    Andrianov, Andrey
    Bex, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 536 - 536
  • [9] CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.
    Pal, Sumanta K.
    Albiges, Laurence
    Rodriguez, Cristina Suarez
    Liu, Bo
    Doss, Jennifer
    Khurana, Sudha
    Scheffold, Christian
    Voss, Martin H.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [10] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial (vol 20, pg 297, 2019)
    Cella, D.
    Grunwald, V
    Escudier, B.
    LANCET ONCOLOGY, 2019, 20 (06): : E293 - E293
12